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of related proteins, to defined genetic manipulation to
create transgenic mouse ªknockouts,º molecular neuro-
biology has underpinned many of our recent insights
into how the brain functions. A consequence of these
developments is the identification and study of genes
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and Jim F. Gusella*²
Molecular Neurobiology Laboratory
The Salk Institute for Biological Studies
La Jolla, California 92037
*Molecular Neurogenetics Unit that cause neurological disease, revealing the role that
affected genes play in normal nervous system functionMassachusetts General Hospital
Charlestown, Massachusetts 02129 and increasing the chances for treatment and cure.
Much work in the field of neurobiology has focused
on the study of the synapse and membrane excitability,
since it is generally believed that the regulation of these
During the last 60 years, our understanding of the brain processes underlies much of higher brain function, in-
has advanced at a spectacular rate due to the efforts of cluding memory, learning, and cognition. Synaptic trans-
researchers trained in physics, mathematics, anatomy, mission is mediated by neurotransmitter molecules re-
physiology, biochemistry, medicine, and most recently leased from the presynaptic cell, which activate two
genetics and molecular biology. The differing perspec- classes of receptors. One is the G protein±coupled re-
tives provided by these diverse specializations have ceptor class, in which ligand binding leads to activation
provided insights into brain function that might have of G proteins and which usually operates in time frames
been missed if neurobiology had been a more homoge- of seconds. The activated G proteins act as second
neous discipline. Neuroscience is now an integral part messengers to regulate the metabolism of the cell, as
of modern biology, thanks in part to the unifying effects well as by directly affecting channel proteins. These
of the newest entrants to the field, geneticists and mo- ªslowº G protein±coupled receptors play a role in modu-
lecular biologists. This review will focus on some of the lating synaptic transmission, cell excitability, and sen-
advances which have resulted from the application of sory systems. The other class of receptors is the neuro-
molecular±genetic techniques to the study of the brain. transmitter- or ligand-gated ion channels, which on
The human brain is estimated to have about a hundred ligand binding undergo a fast conformational change to
billion nerve cells, two million miles of axons, and a open an integral pore within a time frame of 1±100 ms.
million billion synapses, making it the most complex The majority of synaptic transmission in the brain is
structure, natural or artificial, on earth. The advantage mediated by these ªfastº receptors.
and power of the genetic approach is grounded in the Following theold adage towrite about what you know,
fact that the information to build the brain is coded in and because of space limitations, we will restrict de-
the genome, a much simpler structure than the brain tailed discussion to these ªfastº receptors. The history
itself. Mammals are thought to have about one hundred of the use of molecular techniques in neurobiology is in
thousand genes, only a subset of which are expressed many ways encapsulated in the efforts to understand
in the brain, and all of which will soon be sequenced on these channels. We present here a personal historical
completion of the genome project a few years from now. view of the cloning of two neurotransmitter receptors:
In addition, a steady stream of ingenious techniques are the first receptor type cloned, thenicotinic acetylcholine
being developed to manipulate and analyze the genome receptor; and the cloning of the major excitatory recep-
with ever increasing ease and power. tor class in the mammalian brain, the glutamate-gated
Molecular cloning has made it possible to identify the ion channel receptor (GluR). In addition we discuss the
genes and determine the primary structure of many of impact, advantages, and limitations of the molecular
the proteins that mediate synaptic function and mem- approach in the investigation of channel structure and
brane excitability. Site-directed mutagenesis and func- function and the mutations that have been discovered
tional studies in heterologous expression systems have to cause brain dysfunction and disease.
begun to elucidate how proteins such as ion channels
work at the molecular level. High resolution structures
Ion Channel Cloning: an Historical Perspectiveof domains from channels and receptors are being ob-
Cloning of the Acetylcholine-Gated Iontained for the first time, while structures for whole recep-
Channel Receptortor molecules are hopefully not far behind. These struc-
The contribution of cDNA cloning to the determinationtures will make it possible, at long last, to understand
of primary structure is both obvious and overwhelming.the mechanisms underlying channel gating and ion flow
The first receptor cDNAs cloned were four subunits ofat the atomic level. Most recently, the technology of
the nicotinic receptor (nAChR), which is activated by thehomologous recombination or ªgene targetingº has
neurotransmitter acetylcholine as well as nicotine, onemade it possible to create mutations in specific mouse
of the most widely consumed drugs. Cloning was madegenes and in defined brain regions, enabling the dissec-
possible by the serendipitous evolution of two systems.tion of the role of individual proteins in brain function.
The first was the electric organ of Torpedo electric fish,From the initial use of gene cloning to identify families
a modified muscle that uses the nicotinic receptor ex-
pressed at high levels to generate a large current to
paralyze its prey. The secondwas the evolution of snake²To whom correspondence should be addressed.
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Figure 1. Timelines of Cloning and Topological Models
(A) The dates when the first members of each main subfamily were cloned are indicated for four of the main neuronal ion channel families.
The asterisk denotes the publication of the first 55 amino acids of Torpedo nAChR subunit protein sequences (Raftery et al., 1980).
(B) The topological models are placed to indicate the approximate dates that they were first proposed, where space allows. Membrane
domains are shown as either rectangles for transmembrane domains or loops for reentrant domains. Regions implicated in the pore region
are colored green, and the lipid bilayer is indicated in gray. In all cases, the extracellular space is to the top. References for topological
models, reading left to right: nAChR-type: first and fourth (Claudio et al., 1983; Devillers-Thiery et al., 1983; Noda et al., 1983), second (Finer-
Moore and Stroud, 1984), and third (Ratnam et al., 1986); voltage-gated: first (Noda et al., 1984), 8-crossing (data not shown; Greenblatt et
al., 1985; Guy and Seetharamulu, 1986), second (Noda et al., 1986), and third (Guy and Conti, 1990); ATP-gated: first (Brake et al., 1994) and
second (Rassendren et al., 1997); iGluR (ionotropic glutamate receptor): first (Hollmann et al., 1989), second (Seeburg, 1993), and third (Wo
and Oswald, 1994; Hollmann et al., 1994; Bennett and Dingledine, 1995).
peptide neurotoxins, which bind with high affinity and group at Stanford. At around the same time, Shosaku
Numa and colleagues in Japan and Jean-Pierre Chan-specificity to nicotinic receptors in the electric organ.
In the early 1970s, a number of laboratories built affinity geux and colleagues in France used the newly available
protein sequence to clone the nicotinic receptor cDNAs.columns with these neurotoxins and purified nicotinic
receptor from the electric organ of fish in milligram quan- Two years after the work was first started, cDNA se-
quences for all four constituent Torpedo nicotinic recep-tities. The availability of large quantities of nicotinic re-
ceptor made it possible to produce specific antibodies tor subunits were reported by these laboratories in the
space of six months (Ballivet et al., 1982; Noda et al.,and to determine N-terminal protein sequence of the
nicotinic receptor subunits (Devillers-Thiery et al., 1979; 1982, 1983; Claudio et al., 1983; Devillers-Thiery et al.,
1983; Figure 1A). This presaged a flood of nicotinic re-Raftery et al., 1980; reviewed by Karlin and Akabas,
1995). The availability of large qutities of purified recep- ceptor cloning by homology screening, including cDNAs
coding for the related mammalian muscle nicotinic ace-tor also enabled the unambiguous determination of sub-
unit stoichiometry, something that still eludes us for tylcholine receptor expressed at the neuromuscular
junction. One unanticipated discovery was the findingmany of the other receptors, and revealed the first in-
stance of what has turned out to be a common theme that during the development of the neuromuscular junc-
tion there is a switch in the composition of the structureamongst ion channels: receptors made up of a number
of distinct but homologous subunits (Raftery et al., of the nicotinic receptor due to the substitution of the
gamma subunit with the epsilon subunit, conferring new1980).
The work to isolate the cDNAs for the nicotinic recep- biophysical properties to the receptor (Mishina et al.,
1986).tor began in the early 1980s. In the laboratories of Steve
Heinemann and Jim Patrick at the Salk institute, Marc Perhaps one of the most important findings coming
from the cloning of the nicotinic receptor has been theBallivet started a project using immunological methods
and cloning vectors newly developed by Paul Berg's discovery of a large family of related genes that code
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for neuronally expressed nicotinic receptors. Using low kainate, or NMDA (Hollmann and Heinemann, 1994;
stringency homology screening, the laboratories of Sprengel and Seeburg, 1995). The characterization of
Boulter, Patrick, and Heinemann at the Salk Institute recombinant glutamate receptors has revealed a num-
cloned the first nicotinic receptor subunit expressed in ber of unexpected properties. The first was that non-
the brain, a3 (Boulter et al., 1986). Further screening NMDA receptor subtypes have a high permeability to
led to the discovery of a large family of about a dozen calcium ions and that this is regulated by the subunit
nicotinic receptor genes, expressed in almost every composition of the receptor (Hollmann et al., 1991). This
region of the mammalian brain. In addition, these sub- has important implications, since it is well established
units have been demonstrated to assemble in a com- that glutamate receptors are involved in the two best-
binatorial manner, increasing the potential molecular studied examples of synaptic plasticity, long-term po-
diversity of native nicotinic receptors. One of these sub- tentiation (LTP) and long term depression (LTD), which
units, a7 (Couturier et al., 1990; Schoepfer et al., 1990), are thought to play a role in the formation of memory
has proved extremely useful in molecular studies as (Bliss and Collingridge,1993). The elevation of intracellu-
a ªmodelº nicotinic receptor, since it forms functional lar calcium is thought to be the signal that is essential
homomeric channels. for initiating LTP and LTD, evidence that the regulation
The cloning of large numbers of nicotinic receptor of calcium permeability is a crucial process for normal
subunits was unexpected because there was, and still brain function (reviewed by Nicoll et al., 1988; Malenka
is, little evidence for synaptic transmission mediated and Nicoll, 1990). The finding that excess calcium can
by nicotinic acetylcholine receptors in the mammalian lead to neuronal cell death also suggests that the regula-
brain. While synaptic transmission has not been demon- tion of calcium permeability plays an important role in
strated, there is strong evidence that functional nicotinic maintaining the health of the brain (Choi, 1994).
acetylcholine receptors are present in many areas of Permeability to calcium ions in non-NMDA receptors
the brain, including the medial habenula, the interpedun- was found to be largely determined by a single amino
cular nucleus, the retina, the lateral and medial genicu- acid in the ion channel. Receptor subunits containing
late, and the neocortex. Working at the Salk Institute, the neutral amino acid glutamine have high calcium per-
Ana Elgoyhen discovered the latest nicotinic subunit, meability, while subunits containing the basic residue
a9, using a genomic screen. This subunit most likely arginine have low calcium permeability (Hume et al.,
forms a postsynaptic receptor mediating the cholinergic
1991; Verdoorn et al., 1991). As might have been ex-
efferent input to hair cells of the inner ear (Elgoyhen et
pected, the highly calcium-permeable NMDA receptors
al., 1994). Further confirming the functional importance
have the neutral amino acid asparagine at this position.
of nicotinic receptors, a nonopioid analgesic was re-
In AMPA receptors, permeability to calcium is deter-
cently described that acted through selective modula-
mined by the presence or absence of the GluR2 subunit.
tion of neuronal nicotinic receptors (Bannon et al., 1998).
Seeburg's group made the discovery that in GluR2 theMice with null or ªknockoutº mutations in two nicotinic
residue at the Q/R site was determined by RNA editingreceptor subunit genes, a7 and b2, have been reported
(Sommer et al., 1991). The GluR2 gene codes for a gluta-(Orr-Urteger et al., 1997; Picciotto etal., 1998). Both mice
mine at the Q/R site, while virtually all GluR2 mRNA isare viable and have altered physiological responses to
edited to the codon for arginine, resulting in low calciumnicotine in specific areas of the brain. Most significantly,
permeability. Investigation of the mechanism of editingthe mice lacking the b2 subunit have altered avoidance
revealed that the RNA editing process is dependent onlearning and behavioral responses to nicotine (Picciotto
intronic sequences 39 to the edited site (Higuchi et al.,et al., 1998). We expect that with further such character-
1993; Egebjerg et al., 1994). The GluR5 and GluR6 kai-ization of the nicotinic receptors, the data will help to
nate receptors have now also been shown to be regu-explain the powerful and diverse consequences of nico-
lated by RNA editing at the Q/R site (Kohler et al., 1993).tine consumption, including nicotine addiction.
For some glutamate receptor subtypes, the efficiencyCloning of the Glutamate-Gated Ion
of editing has been shown to vary during developmentChannel Receptor
and between different brain regions (Sommer et al., 1991;In 1988, Michael Hollmann came to the Salk Institute
Paschen and Djuricic, 1994). Recently, a similar form ofand began a project to clone the glutamate receptor by
RNA editing has been found in a G protein±coupledlooking for functional expression from pooled cDNAs in
receptor activated by serotonin, the 5-HT2C receptorXenopus oocytes. This ªexpression cloningº method,
(Burns et al., 1997), making RNA editing an increasinglyfirst developed by Shigetada Nakanishi's group in Tokyo
important modulator of brain receptor function.(Masu et al., 1987), was necessitated by the absence
In common with virtually every other field of biologicalof high affinity ligands, which precluded methods rely-
research, transgenic mice are now being generated withing on the initial isolation of protein that had been
targeted mutations to glutamate receptor genes. Muta-used previously toclone neurotransmitter receptors and
tions to the GluR2 gene have provided interesting addi-channels. The successful cloning of the first glutamate-
tions to the debate over the role of editing in receptoractivated channel receptor, GluR1 (Hollmann et al.,
function. Mice lacking the GluR2 gene are viable, and1989), has been followed by the isolation of 17 related
express calcium-permeable AMPA receptors (Jia et al.,genes in mammals, including subunits for the NMDA
1996). In contrast, when the intronic sequence control-receptor, the first of which was cloned by Shigetada
ling editing was removed and replaced with a selec-Nakanishi's group in Kyoto by expression cloning (Mori-
tion marker sequence, the mice died as heterozygotesyoshi et al., 1991). Most of the proteins encoded by
(Brusa et al., 1995). The explanation for this differencethese genes have been shown to participate in func-
tional glutamate receptors selective for either AMPA, awaits the arrival of transgenic mice with ever more
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subtle mutations. The generation of transgenic mice is Ultimately, the question of how many sequences remain
to be discovered will be answered by another scion ofalso beginning to illuminate the function of kainate re-
ceptors, which is poorly understood in part due to the molecular biology, the comprehensive genome sequenc-
ing project.lack of specific drugs. A newly described knockout of
the kainate-selective GluR6 subunit exhibits reduced
locomotion, altered synaptic physiology in the hippo- Ligand-Gated Channel Receptors:
Structures in Fluxcampus, and reduced susceptibility to kainate-induced
seizures (Mulle et al., 1998). Analysis of Primary and Secondary Structure
Despite early (and continued) expectations that three-Unsurprisingly, given the supposed role of NMDA re-
ceptors in a wide range of brain processes, null mutants dimensional structure would routinely be modeled from
primary sequence alone, little has been learned fromfor the NR1 subunit are homozygous lethal (see Ebralidz
et al., 1996; McHugh et al., 1996; Tsien et al., 1996). In deduced primary sequences in isolation. Rather, pattern
matching has been used to identify functionally impor-work that perhaps foreshadows the future power and
elegance of transgenic techniques, Tonegawa and col- tant domains. Initial topological models were based on
hydropathy plots, used to identify those regions mostleagues produced a mouse lacking the NR1 subunit only
in the CA1 region of the hippocampus. The mutation is likely to be in the membrane (Kyte and Doolittle, 1982).
Figure 1B shows the development of these topologicalonly induced after birth, avoiding the complication of
developmental artifacts. Analysis of these mice pro- models for four neuronal channel families. Modifications
were made to these models over time to fit emergingvided genetic evidence for the importance of both the
NMDA receptor and the CA1 region in LTP and spatial (and sometimes contradictory) data. It is also apparent
that models were heavily influenced, often erroneously,learning (Ebralidz et al., 1996; McHugh et al., 1996; Tsien
et al., 1996). This experiment provides the strongest by what was known of the topologies of the other chan-
nel families at the time new subunits were cloned. Theseevidence so far that the most extensively studied form
of synaptic plasticity, LTP, mediates some forms of models therefore demonstrate both the great strength
of molecular biology, the generation of hypotheses andlearning. Null mutations have also been made for the
other NMDA subunits. Mice lacking NR2B die around provision of the tools to test them, and its great weak-
ness, taking the resulting models rather too seriously.birth, while NR2A and NR2C null mutants display vari-
ous, less severe, neuronal deficits (Ebralidz et al., 1996). Which of the current incarnations (Figure 2) will prove
to be correct remains to be seen, but a recurring limita-In work that provides an intriguing insight into the mech-
anisms underlying thesephenotypes, C-terminal trunca- tion of these models has been the difficulty in detecting
short membrane domains. An a helix must be 25±30tions of these same subunits also gave the same pheno-
types as the null mutants (Sprengel et al., 1998). In a final amino acids to cross the bilayer, but b strands or other
extended conformations require only 7±8 residues tounexpected twist, mice lacking the ªorphanº glutamate
receptor subunit d2, which has not yet been demon- cross, and reentrant loops can be any length and are
not necessarily hydrophobic. The general assumptionstrated to form part of a functional glutamate receptor,
had deficits in motor coordination, synapse formation, has been that the membrane domains are a helices.
However, in the 9 AÊ structure of the T. marmorataand LTD (Kashiwabuchi et al., 1995). Taken together,
these results demonstrate the potential for transgenic nAChR, only the pore-lining domain has the electron
density expected of an a helix (Unwin, 1993b). This sug-techniques to confirm the expected, reveal the unex-
pected, and perhaps ultimately help provide a complete gests that the other three hydrophobic domains may
instead cross multiple times as b strands (Figure 2A).genetic dissection of brain function.
Ion Channel Cloning: Too Much of a Good Thing? The presence of b structure is supported by spectro-
scopic measurements of nAChR membrane domainsFollowing the cloning of the nicotinic receptors, cDNAs
for other receptors and channels were soon identified, (GoÈ rne-Tschlenokow et al., 1994), as well as data sug-
gesting at least part of M1 has a nonhelical conformationusing either protein sequence, homology screens, or
functional expression. Beyond the four receptor families (Akabas and Karlin, 1995). To what extent the normally
rectangular representations of transmembrane domainsshown in Figure 1, a large number of cation channels
(both voltage-gated and ªopen channelº) have also been in topological models are in reality zig-zag crossings
(with the intriguing potential for small segments to ex-identified and cloned, many having new and unantici-
pated structures (Figure 2; see also Armstrong and Hille, tend beyond the bilayer), will have to await high resolu-
tion structures.1998, for a review of voltage-gated channels [this issue
of Neuron]). In addition, for many of the ion channels, Tertiary and Quaternary Structure
The three dimensional (3-D) structure of synaptic ionnumerous subunit subtypes have been identified, pro-
viding, at least in theory, the potential for tremendous channels is perhaps the area in which molecular neuro-
biology has had the least impact, but can be expectedfunctional, temporal, and spatial diversity. The possible
combinations appear far in excess of what is required to make the most significant contribution in the future.
Beyond topological models,what we knowabout synap-to explain the known functional diversity, much of which
is in any case derived from artificial pharmacological tic ion channel structure is essentially limited to the
Torpedo nAChR structure (Figure 3). This structure wasdistinctions. This suggests a subtlety of function that
may require additional analytical tools to characterize. determined by cryo±electron microscopy (cryo-EM) us-
ing tubular crystals grown directly from membranes iso-The rate of discovery of new receptor genes has inevita-
bly slowed, and the recent cloning of theGABAB receptor lated from the electric organ of Torpedo electric fish
(Unwin, 1993b). In this structure, the subunits are ar-marks the identification and sequencing of the last
known major receptor class (Kaupmann et al., 1997). ranged in a ring around the central ion channel, and
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Figure 2. A Topological Menagerie of Mammalian Neuronal Channels
Domains are colored as for Figure 1. Except for the nicotinic receptor, no structure is implied for the transmembrane domains (rectangles).
The agonists for the three ligand-gated channels are shown in red.
(A) Nicotinic acetylcholine receptor family. Family includes both anion- and cation-selective channels. Ligand binds in the N-terminal domain,
and all subunits have a conserved 13 amino acid disulfide loop. M1, M3, and M4 are thought to cross as b strands, and M2 as an a helix
(see enlarged region). The channel is formed by the M2 segment from five homologous subunits (see inset).
(B) Ionotropic glutamate receptor family. Channels are permeable to Na1, K1, and Ca21. Ligand binds to two regions, one before M1 and the
other between M3 and M4. The pore is formed by the reentrant loop M2, and current evidence suggests the channel is a pentamer.
(C) P2X ATP-gated receptor. An ATP binding motif is present in the M1±M2 loop. Residues in M2 are involved in the pore (Rassendren et al.,
1997), but the stoichiometry is unknown.
(D) Voltage-gated ion channels (Armstrong and Hille, 1998). Channels highly selective for either Na1, K1, or Ca21. Voltage changes are detected
by S4. The reentrant loop H5 contributes to the pore. Channels have 4-fold symmetry (inset), from either four internal repeats (Na1 and Ca21)
or four subunits (K1).
(E) Inward rectifying K1 channels. Channels are tetrameric (Yang et al., 1995), with two putative membrane domains and a reentrant loop.
There is some evidence of an alternative topology with four membrane domains and no loop (Schwalbe et al., 1997).
(F) Open rectifying K1 channels (Leonoudakis et al., 1998). Channels activate instantaneously, independent of voltage. Membrane domains
and loops identified by hydropathy analysis and homology. Pore suggested to be formed by reentrant loops, although there is no experimental
evidence for this.
each contributes homologous sequences to the pore. see also Armstrong and Hille, 1998). The picture is less
clear for ionotropic glutamate receptors. The size ofThe same basic arrangement is generally assumed to
apply to the other neuronal ion channels, although such the native receptor complex determined by biochemical
techniques is consistent with either four or five subunitsassumptions should be made with caution: for example,
the aquaporin water channels appear by low resolution (Brose et al., 1993). Electrophysiological analysis of
mixed wild-type/mutant receptor populations supportsEM to have a central pore, but the water is fluxed inde-
pendently within each of the four subunits (Li et al., a pentameric structure (Ferrer-Montiel and Montal, 1996;
Premkumar and Auerbach, 1997), although this is far1997).
The muscle nAChR is a pentamer composed of four from universally accepted and is the subject of active
research. The stoichiometry and arrangement of thedifferent subunits in the stoichiometry a2bgd or a2bed in
the case of adult muscle. The other members of this ATP-gated and open rectifying channels shown inFigure
2 is currently unknown.family (see Figure 1A) are also pentamers, demonstrated
either directly using EM (Nayeem et al., 1994; Boess et Further progress on 3-D structure determination has
been limited, primarily due to the difficulties encoun-al., 1995), or indirectly using biochemical or electrophys-
iological techniques (Langosch et al., 1990; Cooper et tered when working with membrane proteins. While het-
erologous expression of soluble proteins has fueled theal., 1991). In contrast, the voltage-gated ion channels
have 4-fold symmetry, either from the four internal re- enormous expansion in structure determination by X-ray
crystallography and nuclear magnetic resonance (NMR)peats in Na1 and Ca21 channels, or by the association
of four subunits as for K1 channels (Figures 2D and 2E; spectroscopy, membrane protein expression remains
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subunits is to use molecular cloning techniques for the
expression of functional subdomains for crystallization.
This technique is being used increasingly to study solu-
ble proteins that have proved refractile to expression or
crystallization. This approach, however, requires accu-
rate identification of functional domains so that indepen-
dently folding units can be stably expressed. Not least
because of the uncertainties in subunit topology, identi-
fication of such domains in ion channels has been slow.
This now appears to be changing, as independent
functional domains from nACh receptors, glutamate re-
ceptors, and voltage-gated channels are now being
identified and expressed (e.g., Kuusinen et al., 1995;
Kim et al., 1997; West et al., 1997). Indeed, the first
domain structures are starting to appear. The structure
of the well-characterized inactivation domain from an
N-type KV channel has been determined by NMR (Antz
et al., 1997), and the structure of the tetramerization
domain from Shaker KV has just been determined by
X-ray crystallography (Kreusch et al., 1998). This struc-
ture reveals an unexpectedly narrow channel at the cen-
ter of the tetramer. If this constriction indeed forms a
cytoplasmic vestibule, the entryway to the pore is not
only quite far from the presumed selectivity filter but is
also only wide enough for dehydrated ions to pass. One
prediction of the earlier biophysical studies is that at
some point the ions must be stripped of H2O as they
pass through the channel (Armstrong and Hille, 1998).
Further important functional insights will undoubtedly
emerge as more structures are determined. It is also
hoped that the next few years will yield a more reliable
system for the recombinant expression of integral mem-
brane proteins, an advance that would help reveal the
structures of these proteins in the same way gene clon-
ing has revealed their sequences over the last 15 years.
Channel Function: a Molecular Perspective
Both ligand- and voltage-gated ion channels share a
common functional paradigm. Detection of neurotrans-
mitters or voltage changes is directly coupled, through
the process of gating, to the opening of the permeation
pathway. For several of these channels, significant prog-
ress has been made in identifying the domains responsi-
ble both for detection or ligand binding and ion perme-
ation. In large measure, this progress has been due to
the application of molecular biology, through the gener-
ation of chimeric proteins and single-site mutants.
Again, we will concentrate here on work relating to the
Figure 3. Three-Dimensional Representation of the Torpedo Nico- ligand-gated channels; the voltage-gated channels are
tinic Acetylcholine Receptor
discussed in detail elsewhere in this issue (Armstrong
The image is based on data at 9 AÊ resolution obtained using cryo±
and Hille, 1998).electron microscopy (Unwin, 1993b). The receptor is viewed from
Ligand-Gated Ion Channel Agonist Binding Sitesthe side (top) and from above (bottom). The top two-thirds of the
Of the three families of neurotransmitter-gated ion chan-receptor (z70 AÊ ) are located synaptically, followed by the mem-
brane-spanning region (colored band) and the smaller cytoplasmic nels (Figures 2A±2C), the agonist binding sites for the
domain. The subunits are located with 5-fold symmetry around the acetylcholine and glutamate receptors are best charac-
central pore, visible in the bottom view. Reproduced from Unwin, terized. In nACh and related receptors, the agonist bind-
1993a, with permission.
ing site is located in the large N-terminal domain before
the first transmembrane domain. A combination of pho-
toaffinity labeling and site-directed mutagenesis has ledproblematic. Indeed, the membrane proteins for which
structures have been determined can all be purified in to the identification of regions involved in the agonist
binding sites of the ion channel receptors for acetylcho-relatively large quantities from natural sources. One al-
ternative to determining the structure of intact channel line (Changeux et al., 1992), glycine (Schmieden et al.,
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1992; Rajendra et al., 1995) and GABA (Buhr et al., 1996; changes, but using current techniques it should soon
be possible to identify the molecular changes underlyingWingrove et al., 1997). In all these receptors, several
this theoretical framework. Part of the difficulty of study-noncontiguous regions have been identified as being
ing gating is that it is part of the same equilibrium withimportant for ligand binding. The acetylcholine binding
ligand binding, makingthe twoevents difficult todissect.site in the Torpedo nicotinic receptor appears from the
Individual residues might affect this equilibrium, andEM structure to be contained within the a subunit, half-
therefore control gating, by stabilizing or destabilizingway up the extracellular domain (Unwin, 1993b). This
the open or closed states or the transition between thecontrasts somewhat with data from photoaffinity label-
two. Intuitively, such residues would be expected toing suggesting the binding site might be located in the
have interacting complements, which might be identi-interface between subunits (Dunn et al., 1993) and evi-
fied by rescue of nonfunctional mutants. Such an ap-dence that mutations within the non-a subunits affect
proach will have to await the generation of putativeagonist binding. However, without a structure it is diffi-
gating mutants. To complicate the issue further, thesecult to distinguish between mutations that are directly
channels also have at least one state (desensitized) inwithin the binding site and those that perturb its struc-
addition to open and closed. In the continued presenceture indirectly.
of agonist, many receptors enter a closed, unresponsiveRegions comprising the agonist binding site of iono-
state. As with gating, the underlying mechanism istropic glutamate receptors have also been identified, in
poorly understood, although two studies have now iden-work that serves as a testament to the power of molecu-
tified regions in the N-terminal domain mediating onelar techniques. This work has been guided by the obser-
type of desensitization in the NMDA receptor (Krupp etvation, made when the first NMDA receptor subunit was
al., 1998; Villarroel et al., 1998). More such studies willcloned, that part of the sequence of glutamate receptor
be needed, as it is likely that the first structures deter-subunits is similar to that of the bacterial glutamine
mined will be of dissected subdomains, missing theperiplasmic binding protein (GlnH). This similarity ex-
linkages crucial to understanding gating and desensiti-tends across two noncontiguous domains of the recep-
zation. A complete description of how channels opentor, one just before the first membrane domain M1 and
and close remains one of the biggest challenges facingthe second between M3 and M4 (by convention count-
the field.ing the reentrant loop as M2), although it is very weak.
The Ion Channel
At the time, these two regions were thought to be on
The pores of the neurotransmitter-gated channels are
opposite sides of the membrane, but changes to the
often visualized as constrictions whose size and charge
topological models later placed them both on the out-
properties determine channel selectivity. Despite their
side (Figure 2B).
different topographical architectures, the ion pores in
The importance of thesedomains in agonistactivation
nicotinic and glutamate channels appear functionally
of GluRs was first demonstrated with chimeras, con- similar. Both receptor classes have wide vestibules at
structed betweenAMPA- and kainate-selective subunits each end of the channel, narrowing to a central selectiv-
(Stern-Bach et al., 1994). This work showed that these ity filter of similar size (Bormann et al., 1987; Villarroel
domains (termed S1 and S2) were together responsible et al., 1995). In molecular terms, a single region has
for agonist selectivity. Based on this work, Kuusinen et generally been labeled as the pore-lining domain, for
al. (1995) joined the GluR2 subunit S1 and S2 domains example M2 in nAChRs and the reentrant loops in the
via a short linker sequence and expressed the construct voltage-gated channels and glutamatereceptors (Figure
in insect cells. This fusion was both soluble and bound 2). While this is convenient, and these regions have been
to [3H]AMPA and other glutamate receptor ligands with elegantly demonstrated to form part of the permeation
the expected affinities, demonstrating the sufficiency of pathway, it is probably an oversimplification. For the
these domains for ligand binding. Furthermore, changes acetylcholine receptor, the architecture of the ion chan-
to residues in both S1 and S2 have been found to affect nel has been investigated using a combination of photo-
receptor function or ligand binding affinities, consistent affinity labeling, subunit chimeras, and single-site mu-
with a role for these domains in agonist activation (e.g., tants. The second transmembrane domain (M2), was
Uchino et al., 1992; Kuryatov et al., 1994; Paas et al., first identified as the pore region using a chimera be-
1996; Laube et al., 1997; Swanson et al., 1997). This tween the Torpedo and bovine nAChR d subunits. The
work has spawned numerous models of the S1/S2 bind- chimeras had the conductance properties correspond-
ingsite, based on structures determinedfor theperiplas- ing to the d subunit M2 region they contained (Imoto
mic binding proteins. Given the level of sequence simi- et al., 1986). Further experiments using open channel
larity, the utility of these models probably lies more in blockers as photoaffinity labels identified residues inter-
providing testable hypotheses than for rational drug de- acting with the pore (reviewed by Unwin, 1993a), and
sign. In the long term, the ability to express the agonist rings of positive charges at each end of the channel
binding domain as a soluble polypeptide will probably were demonstrated to affect ion flux using stepwise
have the greatest impact if and when it leads to a 3-D mutagenesis (Imoto et al., 1988).
structure. The most comprehensive studies are now being done
Coupling of Binding to Channel Opening using the technique of cysteine-scanning mutagenesis.
The mechanisms by which agonist binding is translated This involves the application of molecular biological and
into channel opening is the least understood aspect of chemical techniques, by carrying out systematic muta-
ion channel function, both for the ligand- and voltage- tion of single residues to cysteines and using two cyste-
gated channels. Gating has long been described as a ine-labeling reagents having different permeability prop-
erties. This method provides a powerful technique toªblack-boxº process involving allosteric conformational
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probe the pore region (Akabas et al., 1992; Akabas et techniques, it became possible to determine the chro-
mosomal location of a genetic defect. This is accom-al., 1994). In this way, pore-lining segments have now
plished by tracking the inheritance of naturally occurringbeen identified in a wide range of channel families, and
sequence variations (polymorphisms) in human DNA asuse of this technique should allow the identification of
they are transmitted through the generations of familiesmost channel-lining domains. The results from this work
with an inherited disorder (Gusella, 1986). By identifyingare also often used as evidence of the secondary struc-
statistically significant coinheritance (ªgenetic linkageº)ture of the regions studied. This aspect is less convinc-
of a DNA marker with the genetic defect, it is possibleing, however, given the necessary assumption that the
to infer the presence of the disease gene in the samecysteine is not disturbing the structure and the likelihood
chromosomal vicinity as the polymorphic DNA sequence.that even small distortions in structural elements will
The chromosomal assignment of the disease gene thenaffect the observed labeling pattern.
offers the possibility of identifying the culprit gene onBeyond the Ion Channel
the basis of its location in the genome without any priorIt is known that the ligand-gated receptors can be linked
knowledge of the nature of its protein product. Thisto proteins inside the cell. This was first demonstrated
strategy, which has become knownas positional or loca-for the nicotinic receptor expressed in the electric organ
tion cloning, is applicable to any inherited disorder butand muscle (see Scotlet al., 1993). Recent work has
is particularly important for nervous system disordersdemonstrated that glycine (Kirsch et al., 1991) and gluta-
in which the functional complexity of the target tissuemate receptors are also capable of binding to a diversity
hampers the direct identification of defective proteinsof cytoplasmic proteins (reviewed by Sheng, 1996; Ken-
(Gusella, 1989; Collins, 1990).nedy, 1997). Mary Kennedy and her collaborators found
Mapping the Huntington's Disease Genethat the NMDA receptor is associated with the postsyn-
The first major success with this strategy came withaptic density (PSD) (Moon et al., 1994; reviewed by
the discovery of a DNA marker linked to Huntington'sKennedy, 1997), which triggered a search for proteins
disease (HD), a then-enigmatic autosomal dominant dis-that associate with glutamate receptors. Using the two-
order that was best known as the affliction that felledhybrid genetic screen, Kennedy and Seeburg's groups
folk singer Woody Guthrie (Martin and Gusella, 1986).collaborated to demonstrate binding of the NMDA NR2
HD typically has its onset inmid-life (mean, z40 years)assubunit to the PDZ domain of the PSD-95 protein, ex-
subtle, insidious, adventitious movements and gradually
plaining the previous finding that the NMDA receptor is
progresses to full-blown chorea that consumes all parts
found in the PSD (Kornau et al., 1995). Morgan Sheng
of the body. In addition to the writhing, dance-like move-
and his colleagues demonstrated that the PSD-95 pro-
ment disorder, HD also produces psychiatric changes
tein can causeclustering of NMDAreceptors and Shaker
and cognitive decline with death ensuing z15years after
potassium channels and in a nice experiment showed
onset. The clinical signs are paralleled by a characteris-
that the clusters are disrupted in a Drosophila PSD- tic pattern of progressive neuropathology that devas-
95 null mutant (Tejedor et al., 1997). Huganir and his tates the caudate nucleus and causes extensive neu-
colleagues discovered a protein they termed GRIP, ronal loss throughout the basal ganglia and cortex. In
which binds through PDZ domains to theAMPA receptor 1983, we used two large HD families, one American and
GluR2 subunit (Dong et al., 1997). There is increasing one Venezuelan, to map the HD gene to chromosome
evidence that these receptor-associated proteins are 4, accomplishing the first step in our goal to identify the
involved in a number of functions such as clustering nature of this genetic defect (Gusella et al., 1983, 1984).
and localizing the receptor to specific regions in the cell, Mapping Other Neurogenetic Disorders
regulating receptor function, and catalyzing posttransla- The success in HD demonstrated the power of the ge-
tional modifications of receptors. The discovery that netic linkage strategy and set off a torrent of similar
ligand-gated channel receptors associate with cyto- studies in a wide variety of inherited disorders, including
plasmic proteins raises the possibility that the binding many nervous system diseases. Within the next decade,
of neurotransmitter to the receptor may directly activate linked DNA markers were found for such neurogenetic
a signal transduction pathway within the cell, in addition disorders as Alzheimer's disease, Lou Gehrig's disease
to gating or opening the receptor channel and catalyzing (amyotrophic lateral sclerosis or ALS), neurofibromatosis
ion flow through the membrane. This possibility is sup- 1 and 2, ataxia telangiectasia, and torsion dystonia (Ta-
ported by the recent report that AMPA receptors can ble 1). Ultimately, the ability to attack genetic disease
activate G proteins in the absence of an ion flow (Wang with this approach was a major impetus for the initiation
et al., 1997b). of the Human Genome Project to sequence the entire
genome and to identify all its genes. Indeed, the early
An Alternative Molecular Biological Approach days of the Human Genome Project were aimed at satu-
to Nervous System Function rating the human chromosomes with DNA markers by
Neurologic Disease GenesÐthe Indirect Approach identifying and mapping highly polymorphic stretches
While cDNA cloning based on protein sequence and of dinucleotides and other short repeats in human DNA
functional characteristics was crucial for identifying to facilitate the positional cloning strategy. Disease gene
genes of known importance for brain function, such as isolation was also a driving force for the development
ligand-gated ion channel receptors, a valuable approach of new physical mapping and large-insert cloning tech-
for identifying unknown mutant genes that cause neuro- nologies.
logic dysfunction also emerged in the 1980s. By merging Cloning Based on Map Location
the tenets of Mendelian genetics with the extensive vari- When the HD locus was mapped, the molecular biologi-
cal tools for cloning and assessing several million baseation in human DNAdetectable with molecular biological
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Table 1. Representative Autosomal Neurogenetic Defects Identified from Genetic Linkage Mapping
Year Year Omim
Neurogenetic Disorder Linked Cloned Numbera Protein Product
Alzheimer's disease 1992 1995 104311 presenilin 1
Alzheimer's disease 1995 1995 600759 presenilin 2
Amyotrophic lateral sclerosis 1991 1993 105400 superoxide dismutase 1
Ataxia telangiectasia 1988 1995 208900 novel, similar to phosphatidylinositol
39 kinase and yeast rad3
Nonsyndromic deafness 1 1992 1997 124900 Drosophila diaphanous homolog
Dentatorubro-pallidoluysian 1994 1994 125370 atrophin 1, novel, CAG repeat
Atrophy
Dystonia with diurnal variation 1993 1994 128230 GTP cyclohydrolase 1
Dystonia 1989 1997 128100 torsin A, novel ATP binding protein
Friedreich ataxia 1988 1996 229300 frataxin, novel
Hereditary multi-infarct 1993 1996 125310 Drosophila Notch3 homolog
Dementia
Huntington disease 1983 1993 143100 huntingtin, novel, CAG repeat
Infantile neuronal ceroid 1990 1995 256730 palmitoyl-protein thioesterase
Lipofuscinosis
Juvenile neuronal ceroid 1989 1995 204200 novel
Lipofuscinosis
Myotonic dystrophy 1981b 1992 160900 myotonin kinase
Neurofibromatosis 1 1987 1990 162200 neurofibromin, GAP-related domain
Neurofibromatosis 2 1987 1993 101000 merlin, related to cytoskeletal ERMs
Niemann-Pick C 1993 1997 257220 novel, cholesterol trafficking
Progressive myoclonic epilepsy 1991 1996 254800 cystatin B
Spinal muscular atrophy 1990 1995 253300 novel
Spinocerebellar ataxia 1 1976b 1993 164400 ataxin 1, novel, CAG repeat
Spinocerebellar ataxia 2 1993 1996 183090 ataxin 2, novel, CAG repeat
Spinocerebellar ataxia 3 1993 1994 109150 ataxin 3, novel, CAG repeat
Spinocerebellar ataxia 7 1995 1997 164500 novel, CAG repeat
Stargardt's disease 1992 1997 248200 novel, ABC transporter
Wilson disease 1985b 1993 277900 Cu21 transporting ATPase
a Full clinical descriptions and references can be obtained from Online Mendelian Inheritance in Man on the World-Wide Web at http://
www.ncbi.nlm.nih.gov/Omim.
b Genetic linkage was achieved first with expressed protein markers rather than DNA markers.
pairs of DNA surrounding a linked genetic marker to find shared by the greatest proportion of HD patients, as the
site of the defect. In 1993, a decade after the HD locusan unknown disease gene had not been developed. As
the technology advanced, the search for the HD gene was mapped, the disease gene was identified as a novel
4p16.3 gene with a very unexpected mutation (Hunting-within the terminal 4p16.3 cytogenetic band applied
such novel technologies as pulsed-field gel electropho- ton's Disease Collaborative Research Group, 1993).
The HD Defectresis, chromosome jumping libraries, CpG island librar-
ies, NotI-end clone libraries, cosmid contig construc- More often than not, when a gene is identified by posi-
tional cloning the nature of the defect provides newtion, yeast artificial chromosomes, phage P1 clones,
site-directed chemical cleavage of chromosomal DNA, insight, identifying a previously unsuspected or un-
known protein. A primary example of this came with theradiation hybrid mapping, cDNA selection, exon trap-
ping, and many others (Gusella and MacDonald, 1993). 1993 discovery that one form of Lou Gehrig's disease
(amyotrophic lateral sclerosis) is caused by mutationsOther neurogenetic disorders succumbed to this ap-
proach and a number of interesting and often surprising altering superoxide dismutase 1, an enzyme long stud-
ied but never implicated in the pathogenesis of motordisease genes were found (Table 1). However, HD
proved difficult because of uncertainty in pinpointing its neurons (Rosen et al., 1993). In HD, both the target
protein and thenature of the mutationcame as a surpriseprecise location near the tip of the chromosome 4 short
arm. Ultimately, a 2 Mb candidate region was defined (Gusella et al., 1993; Huntington's Disease Collaborative
Research Group, 1993; Gusella and MacDonald, 1995;and entirely cloned (Bates et al., 1992; Baxendale et al.,
1993), but identification of the HD gene within this large Sharp and Ross, 1996). HD is due to an expanded, unsta-
ble CAG trinucleotide repeat in a gene encoding a largesegment depended on an additional genetic strategy
that has subsequently proved increasingly valuable in novel protein of z350 kDadubbed huntingtin. On normal
chromosomes, the CAG repeat is polymorphic, dis-tracking down disease genes. We used highly polymor-
phic DNA markers to identify a common pattern of alleles playing 10±35 triplets, and is inherited in a Mendelian
fashion, whereas HD chromosomes possess a repeat(or haplotype) that implicated about one-third of seem-
ingly unrelated HD patients from around the world as of .35 triplets that has a mutation rate approaching 1
as it changes in length in most meioses, with a biashaving a common ancestor (MacDonald et al., 1992).
This haplotype analysis ultimately targeted a segment toward size increases. The CAG repeat is within the
huntingtin coding sequence, 17 codons from the aminoof only z150 kb, the region whose marker alleles were
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terminus, where it designates a run of consecutive gluta-
mine residues immediately upstream from a proline-rich
region. The remaining 97% of the protein is not similar
to any others that have been reported, except for a
number of HEAT motifs, domains of unknown function
named for proteins in which they were first identified
by computational analysis (Huntingtin-Elongation factor
3-A subunit of protein phosphatase 2A-TOR1) (Andrade
and Bork, 1995). Huntingtin is expressed widely in both
the nervous system and in other tissues, but its normal
physiological role remains unknown. Mouse knockout
and knock-in experiments have shown that total lack
of huntingtin causes embryonic lethality at gastrulation
(Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995),
whereas reduced levels of huntingtin support further
development but result inabnormal neurogenesis (White
et al., 1997). The expanded polyglutamine segment of
huntingtin, when introduced into the homologous mouse
protein, does not impair these developmental functions
(White et al., 1997). Thus, the human HD mutation ap-
pears to act by a ªgain-of-functionº mechanism.
Interestingly, HD was the second of a growing list of
neurodegenerative disorders found to be caused by a
lengthened polyglutamine segment in unrelated, but
widely expressed, proteins. The first disorder of this
type was spinal bulbar muscular atrophy, caused by a
CAG repeat expansion in the androgen receptor gene
(Brooks and Fischbeck, 1995). Subsequently, expanded
CAG repeats have been found indentatorubropallidoluy-
sian atrophy and spinocerebellar ataxias 1, 2, 3, 6, and
7 (Koshy and Zoghbi, 1997; Gusella et al., 1997). In each
disease, a lengthened run of glutamines alters a protein,
producing a distinctive pattern of neuronal cell loss, with
an age of onset of clinical symptoms that varies inversely
with the number of CAG repeats (Figure 4). Thus, from
the exercise of positional cloning, a common mecha-
nism for neurodegenerative disease has emerged that
appears to have two components: (1) a neuronal toxicity
determined by the number of consecutive glutamines
and (2) a specificity of neuronal loss determined by the
protein context in which the polyglutamine is presented
to the cell.
Figure 4. Increasing CAG Length Decreases Age at Onset in Poly-The polyglutamine segment in mutant huntingtin alters
glutamine Disordersthe physical properties of the protein, disproportionately
Age at onset of neurologic symptoms is plotted against CAG repeatdelaying its migration on SDS-PAGE gels and dramati-
length for spinocerebellar ataxia 2 (SCA2), spinocerebellar ataxia 1
cally increasing its reactivity with certain monoclonal (SCA1), Huntington's disease (HD), dentatorubropallidoluysian atro-
antibodies (Persichetti et al., 1995; Trottier et al., 1995a, phy (DRPLA), and spinocerebellar ataxia 3 (also Machado-Joseph
1995b). A truncated amino terminus of the abnormal disease [SCA3]) based on a compilation of published data (Gusella
et al., 1997).protein will aggregate in vitro and in vivo in transgenic
mice (Davies et al., 1997; Scherzinger et al., 1997). The
altered physical properties of mutant huntingtin are also
protein causes a specific disruption of neuronal functionreflected in the HD postmortem brain with the recent
that triggers a cell death program of which aggregateobservation of dystrophic neurites and intranuclear
formation is a by-product. The latter possibility is moreand cytoplasmic huntingtin immunoreactive inclusions
attractive in explaining the specificity of neuronal loss(DiFiglia et al., 1997). Similar results have been observed
despite widespread expression of the culprit proteinsfor the mutant versions of the other neurodegenerative
and raises the questionas towhether this specifity lies inpolyglutamine disorders (Davies et al., 1998; Ross, 1997).
the normal role of huntingtin and the other polyglutamineHowever, it remains uncertain whether these aggregates
disease proteins in the function of the adult brain.are a cause or a consequence of pathogenesis. The next
More Complex Disorders: Alzheimer's Diseasefew years will see the delineation of whether the altered
and the Psychiatric Disordersphysical properties of these proteins lead directly to the
As the genetic linkage approach has become more pow-development of aggregates that are toxic to theneurons,
or alternatively, whether the physical change in each erful with a dense map of highly polymorphic markers,
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increasing attention is being paid to disorders that may The ligand-gated ion channels offer similar potential
for displaying genetic variation that either causes orbe caused by more than one disease gene or by the
modifies human disease. Table 2 lists the genetic lociinteraction of multiple genes. The strategy has met with
encoding ligand-gated ion channel receptor subunits ingreat success in Alzheimer's disease (AD), where three
human that have been either identified or inferred bydifferent disease genes and one risk factor locus have
work in other species. Their cytogenetic map locationsbeen identified (Goate, 1997; Hutton and Hardy, 1997;
indicate that these receptor genes are spread through-Kim and Tanzi, 1997). AD involves deposition in the brain
out the human chromosomes, with some notable clus-of extracellular amyloid, prompted by a 42 amino acid
ters of genes, such as the GABAA receptor genes onpeptide cleaved from a much larger protein, and devel-
chromosomes 4p, 5q, and 15q, that probably reflectopment of intraneuronal neurofibrillary tangles. Muta-
radiations from a common ancestor by duplication.tions in the amyloid protein precursor gene as well as
Startling Mutations in the Glycine Receptoralterations in two homologous genes encoding preseni-
The first disorder associated with a mutation in a neuro-lins 1 and 2 can increase the production of amyloido-
transmitter receptor was found, not surprisingly, by po-genic peptide and cause early-onset AD. In addition,
sitional cloning.Hyperekplexia (Startle disease; Kok dis-the E4 allele of the apolipoprotein E gene is a significant
ease) is characterized by muscle rigidity of nervousrisk factor for the development of late onset AD. Addi-
system origin, particularly in neonates, and by an exag-tional genetic factors in AD are actively being sought.
gerated startle response to unexpected auditory or tac-A similar approach to psychiatric disorders, most no-
tile stimuli. The underlying genetic defect was firsttably bipolar affective disorder and schizophrenia, has
mapped to chromosome 5q by genetic linkage usingmet with much greater difficulty, perhaps because of
DNA markers (Ryan et al., 1992a). As the symptoms ofmore problematic phenotypic characterization and greater
hyperekplexia are markedly reduced by clonazepam,heterogeneity of genetic contributions. Various reports
this implicated theGABAA receptor gene clusterat 5q33±of genetic linkage and association in each of these dis-
5q35. However, more detailed genetic linkage studieseases have not yet produced a clearcut pathogenic lo-
with physically mapped DNA markers excluded thesecus. However, as a result of global cDNA sequencing
genes, leaving the GLRA1 glycine receptor gene as theanalyses, there are now a substantial number of discrete
prime candidate (Ryan et al., 1992b). Initially, Arg271genes available for analysis as candidates. This re-
was identified as the target of missense alterations in
source suggests that a hybrid strategy that utilizes in-
four families with autosomal dominant hyperekplexia
formation from genetic transmission to assess individ-
(Shiang et al., 1993). Substituting uncharged amino
ual candidate loci (e.g., the transmission-disequilibrium
acids (Leu or Gln) for the charged residue appears to
test) can effectively complement genome-wide linkage
reduce the agonist sensitivity of the receptor (Rajendra
searches to place the hope of major progress in under-
et al., 1994). Mutations affecting other codons have sub-
standing behavioral disorders on the horizon. A major sequently been identified in other families (Shiang et al.,
class of candidates for such studies is the collection of 1995; Elmslie et al., 1996; Milani et al., 1996; Seri et al.,
genes encoding ligand-gated ion channel receptors. 1997).
The homology of human chromosome 5q and mouse
Chr 11 led to the discovery that recessive mutations
Ligand-Gated Ion Channel Receptor Genes
in the mouse homolog of GLRA1 underlie two mouse
in Disease neurologic mutants, spasmodic and oscillator. spas-
Genomic Distribution of Ion Channel modic displays a phenotype similar to hyperekplexia
Receptor Genes and is also caused by a missense mutation (Ryan et al.,
The crucial role of ion channels in the operation of the 1994). oscillator has a more severe phenotype, including
brain and neuromusculature, the high degree of se- progressive tremor and muscle spasms leading to death
quence conservation of ion channel proteins, and the by 3 weeksof age. It is causedby a frameshift-producing
capacity to specifically alter ion channel function all deletion predictedto eliminate the final cytoplasmic loop
support the view that naturally occurring mutations in and transmembrane domain (Buckwalter et al., 1994).
ion channel genes could underlie a variety of human Interestingly, recessive forms of hyperekplexia have
disorders. This was first demonstrated for the muscle now been found in human, including both missense and
voltage-gated Na1 channel a subunit, which coinherits null mutations (Rees et al., 1994; Brune et al., 1996). The
in family studies with hyperkalemic periodic paralysis, a lack of lethality of the latter indicates that the loss of
disorder involving episodic muscle weakness associated functional glycine receptors can be compensated to a
with increased extracellular potassium (Fontaine et al., greater degree in human than in mouse. No mutations
1990). Subsequently, it was recognized that different in other glycine receptor genes have yet been found in
missense alterations in this gene can produce a variety human. However, the discovery of a mutation in the
of other symptoms, including cold-induced muscle stiff- homolog of GLRB in the spastic mouse suggests that
ness (paramyotonia congenita) and fluctuating myoto- these genes should be scanned for alterations in pa-
nia. The individual clinical signs in a given patient pre- tients with hyperekplexia-like symptoms without GLRA1
sumably reflect differential effects of the specific mutations (Kingsmore et al., 1994; Koch et al., 1996).
mutation on the kinetics of Na1 channel function. This Defective Brain and Muscle
general finding has subsequently been demonstrated Acetylcholine Receptors
for a number of other muscle and neuronal voltage- Another brain neurotransmitter-associated defect has
gated ion channels in genetic disorders of both human been found in the CHRNA4 nicotinic acetylcholine re-
ceptor gene on chromosome 20. A null mutation at thisand mouse (Bulman, 1997).
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Table 2. Ligand-Gated Ion Channel Receptor Genes
Receptor Human Map Mouse Map
Human Gene Symbol Subunits Locationa Locationa Human Disorder Mouse Disorderb
Nicotinic
Cholinergic
Receptor
CHRNA1 a1 2q24±q32 2 Congenital myasthenic syndrome
CHRNA2 a2 8p21±q21 14
CHRNA3 a3 15q24 9
CHRNA4 a4 20q13.2±q13.3 2 Nocturnal frontal lobe epilepsy
CHRNA5 a5 15q24 9
CHRNA6 a6 UN UN
CHRNA7 a7 15q14 7
CHRNA8 a8 UN UN
CHRNA9 a9 UN UN
CHRNB1 b1 17p12±p11 11 Congenital myasthenic syndrome
CHRNB2 b2 1p21 3
CHRNB3 b3 8p11.2 UN
CHRNB4 b4 15q24 9
CHRNG g 2q21.1±q21.3 1
CHRND d 2q33±q34 1
CHRNE e 17p13±p12 11 Congenital myasthenic syndrome
Serotonin
Receptor
HTR3 5-HT-3 11q23.1±q23.2 UN
GABAA
Receptor
GABRA1 a1 5q33±q35 11
GABRA2 a2 4p13±p12 5
GABRA3 a3 Xq28 X
GABRA4 a4 4p14±q12 7
GABRA5 a5 15q11.2±q12 7
GABRA6 a6 5q33±q35 11
GABRB1 b1 4p13±p12 5
GABRB2 b2 5q33±q35 UN
GABRB3 b3 15q11.2±q12 7 cleft palate 1
GABRG1 g1 4p14±q12 UN
GABRG2 g2 5q33±q35 11
GABRG3 g3 15q11.2±q12 7
GABRD d 1p UN
GABRE e Xq28 UN
GABRR1 r1 6q14±q21 4
GABRR2 r2 6q14±q12 4
GABRP p UN UN
Glycine
Receptor
GLRA1 a1 5q32 11 Hyperekplexia spasmodic, oscillator
GLRA2 a2 Xp22.1±p21.3 X
GLRA3 a3 UN 8
GLRA4 a4 UN X
GLRB b 4q32 3 spastic
Ionotropic
Glutamate
Receptor
GRIA1 AMPA 1 5q33 11
(GluR1)
GRIA2 AMPA 2 4q32±q33 3
(GluR2)
GRIA3 AMPA 3 Xq25±q26 X
(GluR3)
GRIA4 AMPA 4 11q22±q23 9
(GluR4)
GRID1 d1 UN UN
GRID2 d2 UN 6 lurcher
continued
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Table 2. continued
Receptor Human Map Mouse Map
Human Gene Symbol Subunits Locationa Locationa Human Disorder Mouse Disorderb
GRIK1 kainate 1 21q22.1±q22.2 16
(GluR5)
GRIK2 kainate 2 6q16.3±q21 10 HD modifier
(GluR6)
GRIK3 kainate 3 1p34±p33 4
(GluR7)
GRIK4 kainate 4 11q23 9
GRIK5 kainate 5 19q13.2 7
GRIN1 NMDA 1 9q34.3 2
GRIN2A NMDA 2A 16p13 16
GRIN2B NMDA 2B 12p12 6
GRIN2C NMDA 2C 17q25 11
GRIN2D NMDA 2D UN 7
P2X ATP
Gated
Receptor
P2RX1 1 17p UN
P2RX2 2 UN UN
P2RX3 3 11q12 2
P2RX4 4 12q24 UN
P2RX5 5 UN UN
P2RX6 6 UN UN
P2RX7 7 12q24 UN
Gene locus, mapping and phenotype details were compiled from combining the information available in the public databases on the World-
Wide Web: Online Mendelian Inheritance in Man (OMIM: www.ncbi.nlm.nih.gov/Omim), the Genome Database (GDB; gdbwww.gdb.org/gdb),
Mouse Genome Informatics (MGI; www.informatics.jax.org/index.html), and GenBank (www.ncbi.nlm.nih.gov).
a UN 5 Unknown.
b Excludes targeted (knockout) mutations.
locus was originally implicated in benign familial neona- opening in the presence of acetylcholine, and acetylcho-
line-independent channel opening. These changes com-tal convulsions (Beck et al., 1994), but the subsequent
discovery of missense mutations in a nearby voltage- promise normal transmission at theneuromuscular junc-
tion and lead to endplate myopathy, presumably bygated K1 channel gene has raised doubts about this
finding (Biervert et al., 1998; Singh et al., 1998). However, cationic overload. Interestingly, a recessive myasthenic
syndrome involving endplate acetylcholine receptor de-alteration of CHRNA4 does cause a separate disorder,
autosomal dominant nocturnal frontal-lobe epilepsy, a ficiency is caused by CHRNE mutations associated with
decreased subunit production, decreased affinity forpartial epilepsy typified by brief, violent, sleep-associ-
ated seizures (Steinlein et al., 1995, 1997). A missense acetylcholine, diminished acetylcholine-induced chan-
nel opening, and/or suppression of desensitization (En-mutation and a codon insertion, both affecting M2 of
the a4 subunit, each can cause this phenotype, although gel et al., 1996b; Ohno et al., 1997). In this case, overall
dysfunction of the neuromuscular junction is mitigatedit is not clear whether this effect is due to reduced
function or hyperactivity of the receptor (Forman et al., by continued expression of the fetal CHNRG gene.
Disease Candidates in Waiting1996).
Another route to identifying the genetic basis of inher- No inherited human disorder has been connected with
a definite mutation in a GABAA receptor gene, althoughited disorders is direct sequencing of reasonable candi-
date genes without prior linkage mapping of the genetic inactivation of the GABAB3 homolog in mouse produces
a developmental deficit leading to cleft palate (Culiat etdefect. Among the ligand-gated ion channels, this has
been most successful in the congenital myasthenic syn- al., 1995). Similarly, no pathogenicmutation has yet been
demonstrated in a human glutamate receptor gene, al-dromes, in which the endplate acetylcholine receptor is
an obvious candidate. In the autosomal dominant slow though mouse knockoutmutations of these genes cause
subtle to severe neurologic symptoms. Interestingly, po-channel myasthenic syndrome, a variety of missense
mutations have been found in three different subunit sitional cloning revealed recently that the lurcher mouse,
which displays ataxia due to loss of cerebellar Purkinjegenes, CHNRA1, CHNRB1, and CHRNE (Gomez and
Gammack, 1995; Ohno et al., 1995; Sine et al., 1995; cells during postnatal development, is caused by a mis-
sense mutation in the GRID2 homolog (Zuo et al., 1997).Engel et al., 1996a; Gomez et al., 1996; Croxen et al.,
1997; Milone et al., 1997; Wang et al., 1997a). These The heterozygous substitution of Thr in place of a highly
conserved Ala residue in transmembrane domain 3 ofmutations provide a natural structure±function experi-
ment, in which different alterations have variously been the delta2 glutamate receptor leads to a large constitu-
tive inward current, providing a geneticmodel for excito-implicated in producing increased affinity for acetylcho-
line, decreased rate of acetylcholine dissociation, en- toxic cell death in the nervous system. Mutations in
glutamate receptor genes may ultimately be found tohanced steady-state desensitization, prolonged channel
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Akabas, M.H., Stauffer, D.A., Xu, M., and Karlin, A. (1992). Acetylcho-cause neurodegenerative disease in human. However,
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suggested that GluR6 variation may have a mild effect the entire M2 segment of the a subunit. Neuron 13, 919±927.
on age of onset in Huntington's disease, although the Andrade, M.A., andBork, P. (1995). HEAT repeats in theHuntington's
primary determinant of disease severity is the length of disease protein. Nature Genet. 11, 115±116.
the HD gene's expanded CAG repeat (Rubinsztein et Antz, C., Geyer, M., Fakler, B., Schott, M.K., Guy, H.R., Frank, R.,
al., 1997). Ruppersberg, J.P., and Kalbitzer, H.R. (1997). NMR structure of inac-
tivation gates from mammalian voltage-dependent potassium chan-The capacity of the ligand-gated ion channels to mod-
nel. Nature 385, 272±275.ify synaptic function suggests that they may also play
Armstrong, C.M., and Hille, B. (1998). Voltage-gated ion channelsan important genetic role in behavioral disorders, such
and electrical excitability. Neuron 20, this issue, 371±380.as schizophrenia, depression, and anxiety, but to date
Ballivet, M., Patrick, J., Lee, J., and Heinemann, S. (1982). Moleculartests of genetic association have not provided conclu-
cloning of cDNA coding for the g subunit of Torpedo acetylcholine
sive evidence of their involvement. As these are all com- receptor. Proc. Natl. Acad. Sci. USA 79, 4466±4470.
plex and probably heterogeneous disorders, any single Bannon, A.W., Decker, M.W., Holladay, M.W., Curzon, P., Donnelly-
receptor defect may operate in only a small proportion Roberts, D., Puttfarcken, P.S., Bitner, R.S., Daiz, A., Dickenson, A.H.,
of cases, and only in interaction with other genetic and/ Porsolt, R.D., et al. (1998). Broad-spectrum, non-opioid analgesic
activity by selective modulation of neuronal nicotinic acetylcholineor environmental factors. Consequently, normal poly-
receptors. Science 279, 77±81.morphic variation in the ion channel receptors may lead
Bates, G.P., Valdes, J., Hummerich, H., Baxendale, S., Le Paslier,to combinations of alleles that have behavioral conse-
D.L., Monaco, A.P., Tagle, D., MacDonald, M.E., Altherr, M., Ross,quences as a result of quite subtle effects on ion channel
M., et al. (1992). Characterization of a yeast artificial chromosome
function. Discovery of such geneticeffects maybe immi- contig spanning the Huntington's disease gene candidate region.
nent, as improvements in technology have made it feasi- Nature Genet. 1, 180±187.
ble to sequence individual genes in large populations Baxendale, S., MacDonald, M.E., Mott, R., Francis, F., Lin, C., Kirby,
of phenotyped individuals. In any event, it is likely that S.F., James, M.,Zehetner, G., Hummerich, H., Valdes, J., et al. (1993).
A cosmid contig and high resolution restriction map of the 2 mega-geneticists have barely scratched the surface of the full
base region containing the Huntington's disease gene. Naturerange of human phenotypes that are associated with
Genet. 4, 181±186.sequence differences in the ligand-gated ion channel
Beck, C., Moulard, B., Steinlein, O., Guipponi, M., Vallee, L., Mont-genes.
pied, P., Baldy-Moulnier, M., and Malafosse, A. (1994). A nonsense
mutation in the alpha4 subunit of the nicotinic acetylcholine receptor
The Future (CHRNA4) cosegregates with 20q-linked benign neonatal familial
If the past is any guide to the future, then the continued convulsions (EBNI). Neurobiol. Dis. 1, 95±99.
application of molecular neurobiology will answer many Bennett, J.A., and Dingledine, R. (1995). Topology profile for a gluta-
mate receptor: three transmembrane domains and a channel-liningof the questions we now have, as well as revealing new
re-entrant membrane loop. Neuron 14, 373±384.and unexpected aspects of channel function. It is to be
Biervert, C., Schroeder, B.C., Kubisch, C., Berkovic, S.F., Propping,hoped that this research will lead to the elucidation of
P., Jentsch, T.J., and Steinlein, O.K. (1998). A potassium channelthe molecular processes underlying neuronal disease,
mutation in neonatal human epilepsy. Science 279, 403±406.
and in the near future we hope to see the fruit of this in
Bliss, T.V., and Collingridge, G.L. (1993). A synaptic model of mem-
new therapies for the now devastating neurodegenera- ory: long-term potentiation in the hippocampus. Nature 361, 31±39.
tive and mental disorders. There is an additional hope, Boess, F.G., Beroukhim, R., and Martin, I.L. (1995). Ultrastructure
or some might say a fantasy: molecular genetics gives of the 5-hydroxytryptamine3 receptor. J. Neurochem. 64, 1401±1405.
us the power to use engineering design to alter brain Bormann, J., Hamill, O.P., and Sakmann, B. (1987). Mechanism of
function and perhaps the ªmindº itself. By applying ge- anion permeation through channels gated by glycine and g-amino-
butyric acid in mouse cultured spinal neurons. J. Physiol. 385,netics with the development of new tools to study be-
243±286.havior in the mouse, we may be able to discover impor-
Boulter, J., Evans, K., Goldman, D., Martin, G.,Treco, D., Heinemann,tant principles about brain function that will lead to a
S., and Patrick, J. (1986). Isolation of a cDNA clone coding for abetter understanding of our own brain and what makes
possible neural nicotinic acetylcholine receptor a-subunit. Nature
us human. 319, 368±374.
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